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Toxoplasma-IgM AND IgG-AVIDITY IN SINGLE SAMPLES FROM AREAS WITH A HIGH INFECTION
RATE CAN DETERMINE THE RISK OF MOTHER-TO-CHILD TRANSMISSION
Myrian Morussi REIS(1,2,3), Maria Madalena TESSARO(1) & Pedro Alves D’AZEVEDO(2)
SUMMARY
Anti-Toxoplasma IgG-avidity was determined in 168 serum samples from IgG- and IgM-positive pregnant women at various
times during pregnancy, in order to evaluate the predictive value for risk of mother-to-child transmission in a single sample, taking
the limitations of conventional serology into account. The neonatal IgM was considered the serologic marker of transmission.
Fluorometric tests for IgG, IgM (immunocapture) and IgG-avidity were performed. Fifty-one of the 128 pregnant women tested
gave birth in the hospital and neonatal IgM was obtained. The results showed 32 (62.75%) pregnant women having high avidity,
IgM indexes between 0.6 and 2.4, and no infected newborn. Nineteen (37.25%) had low or inconclusive avidity, IgM indexes
between 0.6 and 11.9, and five infected newborns and one stillbirth. In two infected newborns and the stillbirth maternal IgM
indexes were low and in one infected newborn the only maternal parameter that suggested fetal risk was IgG-avidity. In the present
study, IgG-avidity performed in single samples from positive IgM pregnant women helped to determine the risk of transmission at
any time during pregnancy, especially when the indexes of the two tests were analysed with respect to gestational age. This model
may be less expensive in developing countries where there is a high prevalence of infection than the follow-up of susceptible
mothers until childbirth with monthly serology, and it creates a new perspective for the diagnosis of congenital toxoplasmosis.
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INTRODUCTION
The risk of mother-to-child transmission of Toxoplasma gondii and
the severity of sequelae in congenital infection have been correlated
with gestational age in which maternal seroconversion occurs4.
Significant reduction in the frequency and severity of disease at birth
have been associated with in utero treatment of infected fetuses1,16,
even though treatment does not prevent transmission of the parasite24.
The high prevalence of Toxoplasma infection in pregnant women from
Porto Alegre has led to the use of serological screening in the local
health care system12.
IgM antibodies may appear earlier and decline more rapidly than
IgG antibodies and are frequently the first class of antibodies detected
after primary infection17. Despite the wide distribution of commercial
kits to measure IgM antibodies, they lack standardization; therefore,
quantitative results from different manufacturers cannot be compared.
Several methods for IgM detection still have a high frequency of false-
positives and in some patients, positive IgM is “residual”, detected
during the chronic phase of infection. A positive IgM result in an
isolated sample can be interpreted as a true-positive in acute infection,
a true-positive in chronic infection or as a false-positive17.
The IgM indexes measured in acute infection are significantly
higher than those in residual ones25. With ELFA- enzyme-linked
fluorescent assay, VIDAS system, increasing IgM indexes or over 3.5
were observed in acute infection, indexes between 3.0 and 3.5 in the
transitional phase, and indexes between 0.65 and 3.0 in latent infection2.
An IgM test should be performed by a procedure with minimal
nonspecific reaction, such as IgM-capture EIA2,5,25. The algorithm for
serodiagnosis of toxoplasmosis in the USA includes an IgM
measurement when time of infection needs to be defined. If IgM is
positive at elevated indexes, infection has probably occurred in the
prior three to six months. If it is positive at low indexes it may be a
false-positive, be related to infection acquired in the prior two years or
be related to reinfection. If it is negative, infection has occurred more
than two years before. In individuals presenting with low IgM indexes,
it was suggested by the authors that a second sample be collected,
with both processed together to safely detect an increase of antibody
levels25. In pregnant women with low IgM indexes, it is difficult to
determine the time of infection and exclude the possibility of
transmission.
In 1989, HEDMAN et al.9 introduced the IgG-avidity test to help
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diagnose acute infection based on the binding strength of specific IgG
to a multivalent antigen of the parasite, which is produced at low
concentrations after primary infection and increases over time. High
avidity at the beginning of pregnancy has been used as a parameter to
exclude post-conception infection9,10.
The risk of acute infection, parasitemia and mother-to-child
transmission has been associated with high levels of IgG14, presence
of IgM14 or IgM at high levels2,14,25 and low IgG-avidity5,9,11,13,18,22,23.
Serological responses, however, follow diverse, individual rhythms.
Low avidity, as well as the presence of IgM can be detected long after
primary infection in some individuals. High and even very high IgG is
not always observed in acute infection, especially during the first
weeks11.
 At Hospital Materno-Infantil Presidente Vargas in Porto Alegre,
serology for toxoplasmosis is requested at the first prenatal visit, but
the follow-up of susceptible pregnant women is poorly conducted or is
not done at all. Samples from positive IgG and IgM pregnant women,
who start prenatal care late or are serologically tested only at the time
of labor, are commonly seen. It would be of value if the patients’
immune status could be obtained of these single samples, bearing in
mind that ultrasonography, amniocentesis and PCR (polymerase chain
reaction) are requested based on it.
The aim of this study was, therefore, to evaluate IgG-avidity in
samples from IgG- and IgM-positive pregnant women in relation to its
capacity to identify the risk of mother-to-child transmission of
Toxoplasma from single samples, requested at any time during
pregnancy, considering the limitations of conventional serology.
Specific IgG levels and specific IgM and IgG-avidity indexes were
analyzed, and neonatal IgM was used as the serologic marker of mother-
to-child transmission.
PATIENTS AND METHODS
Anti-T. gondii IgG-avidity was prospectively determined in all
positive IgG and IgM samples obtained from pregnant women at their
first prenatal visit to Hospital Materno-Infantil Presidente Vargas in
Porto Alegre, Rio Grande do Sul, Brazil, between 2000 and 2004,
regardless of gestational age. Fifty-one mothers gave birth at the
hospital. A newborn blood sample was drawn to process specific IgG
and IgM.
IgG anti- T. gondii was performed using the MEIA, AxSYM®
SYSTEM Toxo IgG commercial kit (Abbott Laboratories, Chicago,
IL, USA). Results were expressed as International Units per milliliter
(IU/mL), negative: < 2.0, positive: > 3.0, inconclusive: between 2.0
and 3.0.
IgM anti- T. gondii was performed using the ELFA, VIDAS TOXO
IgM, TXM commercial kit (bioMérieux SA, Lyon, France). The results
were expressed as indexes, negative: < 0.55, positive: > 0.65,
inconclusive: between 0.55 and 0.65.
VIDAS AVIDITY was also performed using the ELFA commercial
kit and the results were expressed as indexes, low: < 0.2, high: > 0.3,
inconclusive: between 0.2 and 0.3.
Newborn specific IgG and IgM were processed with the same
techniques.
Fisher’s Exact test was used to analyze (a) the association between
categorized IgM and transmission, (b) categorized IgM and categorized
avidity and (c) categorized avidity and transmission. The Student t test
was used to analyze the association between avidity index and
transmission. The Pearson correlation was used to analyze the
correlation between IgM and avidity indexes.
The project was approved by the Ethics Committee of the Hospital
Materno-Infantil Presidente Vargas.
RESULTS
IgG-avidity was performed on 168 samples from positive IgG and
IgM pregnant women (about 2.5% of the total number of serologies
performed during this period) and was high in 128 (76%) and low or
inconclusive in 40 (24%). The gestational age was known in 105 women
(62.5%) of which 33 (31.4%) were in the first, 36 (34.3%) in the second
and 36 (34.3%) in the third trimester of gestation. Fifty-one mothers
(30%) gave birth at the hospital, thus making it possible to obtain
neonatal IgM.
Among the 128 pregnant women with high avidity, 32 gave birth
at the hospital. IgG levels ranged from 58 to 8,832 IU/mL and IgM
indexes ranged between 0.65 and 2.4. Eighteen mothers had low IgM
indexes (between 1.0 and 3.0) and 14 only very low amounts of IgM
(between 0.65 and 0.9). Eleven mothers were in the first, seven in the
second and 14 the third trimester of gestation. Neonatal IgM tests were
negative in all newborns.
Among the 40 pregnant women with low or inconclusive avidity,
19 gave birth at the institution (Table 1). IgG levels ranged from 106
to 3,356 IU/mL and IgM indexes from 0.65 to 11.9. Six mothers had
IgM indexes higher than 3.5 and avidity very low (M1 to M6), 11 had
low IgM indexes (between 1.0 and 3.0) and two only traces of IgM
(between 0.65 and 0.9). Two mothers were in the first, six were in the
second and 11 were in the third trimester of gestation.
Five positive IgM newborns (M1, M2, M5, M11 and M13) and
one stillbirth (M12) resulted from these mothers. In three infected
newborns (M1, M2 and M5), the maternal IgM indexes were extremely
high and in two infected newborns (M11 and M13) and the stillbirth
(M12) these indexes were low. Maternal serologies of M2 and M5
were very similar: low levels of IgG and high indexes of IgM.
According to the Fisher’s Exact test, there is a statistically
significant association between categorized IgM of mothers (index
higher than 3.0) and transmission (p < 0.028), neonatal IgM being the
serologic marker of transmission. High IgM is predicted to result in a
higher number of infected children than low or inconclusive IgM. There
is also a statistically significant association between categorized IgM
and categorized avidity (p < 0.001), high IgM being associated with
low avidity and vice-versa. There is also an association between
categorized avidity and transmission (p < 0.001), low avidity associated
with transmission and high avidity associated with lack of transmission
using the manufacturer threshold of 0.2. Reducing the threshold to
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0.15 increases the association between low avidity and transmission.
According to the Student t test, there is an association between the
avidity index and transmission (p < 0.001), with a lower avidity index
associated with a higher chance of transmission.
According to the Pearson correlation, there is a significant
correlation between IgM and avidity indexes, moderately and inversely.
Thus, a high avidity index corresponds to a low IgM index and vice-
versa (r = - 0.548, p < 0.001). The relationship between IgM and avidity
indexes when avidity is low, is shown in Fig. 1 (r = - 0.472; p = 0.041),
and when it is high, in Fig. 2 (r = - 0.275; p = 0.128).
DISCUSSION
When routine testing for Toxoplasma antibodies is performed in
pregnant women, the first serum sample is usually taken at the first
antenatal health care visit confirming pregnancy, usually between eight
and twelve weeks. At Hospital Materno-Infantil Presidente Vargas, the
first serum sample from a pregnant woman is frequently obtained later,
after 20 weeks of pregnancy, or even as a parturient. If the presence of
Table 1
Mothers with positive or inconclusive IgM and low or inconclusive avidity, according to gestational age and neonatal IgM
Mother Gestational IgG IU/mL IgM Avidity Neonate IgM
age-trimester ELFA MEIA indexes indexes indexes
M1 3rd 3356 > 300 11.9 0.05 positive (7.9)
M2 3rd 112 173 6.7 0.04 positive (6.5)
M3 1st 2656 > 300 6.3 0.16 negative
M4 1st 1060 > 300 4.6 0.04 negative
M5 3rd 155 > 300 4.5 0.04 positive (9.3)
M6 3rd 748 > 300 4.1 0.08 negative
M7 3rd 560 > 300 3.0 0.08 negative
M8 2nd 176 100 2.6 0.09 negative
M9 3rd 352 > 300 2.5 0.15 negative
M10 3rd 360 > 300 2.5 0.22 negative
M11 2nd 244 > 300 2.4 0.13 positive (1.4)
M12 3rd 2000 > 300 1.9 0.07 stillbirth
M13 3rd 212 165 1.8 0.02 positive (2.9)
M14 2nd 148 79 1.8 0.29 negative
M15 2nd 280 277 1.7 0.08 negative
M16 2nd 820 > 300 1.0 0.17 negative
M17 2nd 460 > 300 1.0 0.19 negative
M18 3rd 1416 > 300 0.7 0.18 negative
M19 3rd 106 28 0.6 0.28 negative
Fig. 1 - The moderate and inverse correlation between IgM and avidity indexes obtained in
the samples with low avidity (r = - 0.472, p = 0.041).
Fig. 2 - The non-significant correlation between IgM and avidity indexes, obtained in samples
with high avidity. (r = - 0.275, p = 0.128).
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IgM antibodies in single samples is the parameter used to identify
acute infection, many women will be falsely identified as probably or
possibly infected, according to the classification system produced by
the working group of the European Research Network on Congenital
Toxoplasmosis14 , and they will undergo unnecessary diagnostic
amniocentesis and/or antiparasitic treatment.
For these reasons, positive IgG and IgM in single samples were
analyzed with regard to three parameters, IgG in IU/mL by MEIA and
ELFA and IgM and IgG-avidity indexes by ELFA. The parameters were
compared to neonatal infection determined by neonatal IgM, in order
to assess the risk of mother-to-child transmission. The absence of
neonatal IgM in the 32 infants born to mothers with high avidity, low
indexes of IgM and even very high levels of IgG reinforces the
importance of high avidity in evaluating the risk of transmission in
any gestational age.
The presence of neonatal IgM in five infants born to mothers with
low avidity and one stillbirth reinforces the importance of low avidity
concerning the risk of transmission when it is measured in IgM-positive
pregnant women. High indexes of IgM (M1, M2 and M5) also support
the importance of IgM levels concerning the risk of transmission. M3
and M4 were under 20 weeks and their neonates were IgM negative,
probably because the risk of transmission is lower in the first half of
pregnancy.
The VIDAS avidity test has been standardized and optimized to
exclude recent seroconversion in pregnant women presenting with
elevated anti-Toxoplasma IgM levels in the first trimester of pregnancy6.
The association between categorized avidity and transmission (p <
0.001) using the manufacturer recommended threshold of 0.2 is
increased when reducing the threshold from 0.2 to 0.15, with six cases
of fetal transmission resulting from 12 mothers.
Without measuring avidity, the infected infants born to M11 and
M13 with low levels of IgG and low indexes of IgM would not have
been detected during pregnancy. In one infected newborn (M13), the
only maternal parameter that strongly suggested fetal risk was IgG-
avidity. These are the results from conventional serologies, most
difficult to correlate with the risk of transmission, as IgM can be residual
in a descending curve.
The moderate and inverse correlation between IgM and avidity
indexes obtained in the samples with low avidity (Fig. 1) in this series
(r = - 0.472, p = 0.041) is very similar to the correlation found by
JENUM et al.11 between avidity indexes and estimated the time of
infection (r = 0.46). The correlation between IgM and avidity indexes
obtained in the samples with high avidity (Fig. 2) in this series
(r = - 0.275, p = 0.128) is non-significant, meaning that high avidity
did not show any relationship with IgM. There was a better association
of transmission with avidity (p < 0.001) than with categorized IgM,
index higher than 3.0 (p < 0.028).
The dynamics of antibody formation must be remembered in
interpreting the maternal results, especially in single samples.
Considering the screening techniques used at Hospital Materno-Infantil
Presidente Vargas, the sensitivity of MEIA-IgG3 and the capture design
of ELFA-IgM2, the risk of mother-to-child transmission is related to
the time of antibody appearance: (1st) IgM > 3.0/ IgG < 20 UI/mL,
(2nd) IgM > 3.0/ IgG between 20 and 300 UI/mL, (3rd) IgM > 3.0/ IgG
> 300 UI/mL, (4th) IgM < 3.0/ IgG positive at any level. The last group,
therefore, benefit most from obtaining the result of avidity, with low
avidity indicating a higher risk, high avidity indicating a lower risk of
transmission.
In JENUM et al.11 series, high IgG-avidity (above 20%), can be
used to exclude recent acute infection in the first 20 weeks, which
reinforces the findings by LAPPALAINEN et al.13 who found a positive
predictive value of 100% for high avidity in the five preceeding months.
In FLORI et al. series6, the increase of avidity indexes was low; the
average time to reach the threshold of 0.3 was 14.2 months. No women
reach this threshold either at four months or at six months after
seroconversion. According to the authors, it is justifiable to decrease the
threshold for exclusion of a recent infection of less than four months to
0.2 and use the company threshold of 0.3 for exclusion of infections
which have occurred more than six months ago. The kinetics of the
avidity test in five groups of women based on the type and duration of
treatment given has also been evaluated and there was no significant
difference when comparisons were made between the groups.
The best approach to prevent and control congenital toxoplasmosis
is not clear. In France, a country with a high prevalence of infection,
prevention is performed through serological screening and follow-up
of susceptible mothers until childbirth with monthly serology1,16,21.
Seroconversion indicates maternal acute infection. Parasite detection
in amniotic fluid can be performed by in vitro culture, mouse inoculation
and PCR to confirm fetal infection.
PCR for detection of T. gondii has revolutionized prenatal diagnosis
by enabling an early diagnosis to be made, thereby avoiding the use of
more invasive procedures on the fetus, thanks to its sensitivity,
specificity and rapidity7,17. However, the results of a European
collaborative study highlighted the lack of homogeneity between PCR
protocols and performance and underlined the need for an external
quality assurance scheme19. There are, also, marked differences in PCR
sensitivity depending on gestational age at the time of the
amniocentesis. Furthermore, PCR on amniotic fluid is not
recommended for HIV-infected women, because of the risk of
transmitting the HIV virus to the fetus during the procedure17.
DUNN et al.4 analyzed the status of congenital infection in 554
cases. The overall maternal-fetal transmission rate was 29%, which
masked a sharp increase in risk from 6% at 13 weeks to 72% at 36
weeks. Women who seroconverted at 24-30 weeks carried the highest
risk (10%) of having a congenitally infected child with early clinical
signs and at risk of long-term complications.
Most infected newborn babies do not have overt signs of disease at
birth but are at substantial risk of developing long-term sequelae:
chorioretinal disease in up to 85% of infected children and neurological
abnormalities. Marked reductions in frequency and severity of disease
at birth have been associated with in utero treatment. Significant
reductions in expected long-term complications have been associated
with extended post-natal treatment regimens started in the newborn
period or as a continuation of in utero treatment1,16,21.
REIS, M.M.; TESSARO, M.M. & D’AZEVEDO, P.A. - Toxoplasma-IgM and IgG-avidity in single samples from areas with a high infection rate can determine the risk of mother-to-child
transmission. Rev. Inst. Med. trop. S. Paulo, 48(2):93-98, 2006.
97
Despite the use of advanced methods, some cases of congenital
toxoplasmosis cannot be detected early, which underlines the
importance of careful follow-up of newborns at risk21. In Denmark, a
country with a low prevalence of infection, a neonatal screening
programme based solely on detection of Toxoplasma-specific IgM
antibodies evaluated from the PKU card could identify more than 75%
of infected infants born to untreated mothers15. This strategy could be
the most appropriate one for countries with a low prevalence of
infection8,15. In the United States, an isolated serum sample, often
obtained either late in the first trimester or during the second or third
trimester, is the only source of information on whether the fetus is at
risk26.
RICCI et al.20 compared the results of the two approaches in a
population with a high infection rate in order to evaluate the
effectiveness of these strategies in 5,288 susceptible pregnancies, 188
identified as infected, and 9,730 neonates. In this series, neonatal
screening for toxoplasmosis seems to be less effective than pregnancy
screening. In a study from Porto Alegre, neonatal screening identified
cases of congenital toxoplasmosis acquired and transmitted in late
pregnancy and undetected by prenatal screening12.
There is a high prevalence of congenital toxoplasmosis in Porto
Alegre12. Prevention programs using single samples should be
approached carefully. It is necessary to choose the best combination
of assays11,22. Because the IgG-avidity test is largely employed as a 2nd
level test, 117 cases of toxoplasmosis in pregnancy divided into the
risk categories according to Lebech’s criteria were re-examined
including avidity that could define 77 out of 117 (65.8%) with only a
single serum sample. The avidity test proved to be a useful method to
classify the Toxoplasma infection in a single serum sample, especially
during pregnancy23.
A large European multicenter study22 explored the diagnostic
performances of 20 antibody assays and their combinations in assessing
the time of primary infection with T. gondii. The sample criteria
permitted evaluation of test performance in terms of clinical sensitivity
and specificity rather than analytical sensitivity and specificity.
Excellent diagnostic performances, specificity near 99% maintaining
sensitivities of 95% or higher, were reached by sequential use of highly
sensitive IgM assays and methods that explored IgG quality, differential
agglutination and avidity assays. The prerequisite for IgG seropositivity
may have ruled out samples in the first two weeks of infection, when
not all the antibody isotypes have yet been expressed.
For Brazilian public health institutions, the best serological model
to prevent congenital toxoplasmosis using single samples would be
analyzing for IgG and IgM antibodies using sensitive methods. Avidity
should be done in all positive IgM serologies. High avidity helps to
exclude acute infection in the last 20 weeks. Low avidity is associated
with risk of transmission which increases during gestation; therefore,
neonatal IgM should be performed in all low IgG-avidity maternal
serologies. Negative neonates, even asymptomatics, should be carefully
followed-up during the first year to exclude congenital toxoplasmosis.
CONCLUSIONS
From these results it can be concluded that IgG-avidity performed
in single samples from positive anti-Toxoplasma IgM pregnant women
can determine the risk of transmission at any time during pregnancy,
especially if the indexes of the two tests are analysed compared to
gestational age. This model may be less expensive in developing
countries with a high infection rate than the follow-up of susceptible
mothers until childbirth with monthly serology, and it creates a new
perspective for the diagnosis of congenital toxoplasmosis.
RESUMO
Avidez de IgM e IgG de Toxoplasma em amostras de áreas com
alta taxa de infecção pode determinar risco de transmissão
materno-fetal
A avidez de IgG anti-Toxoplasma foi realizada em 168 amostras
IgG e IgM positivas de gestantes, coletadas em qualquer período da
gestação, para avaliar o valor preditivo do risco de transmissão materno-
fetal em amostra única, considerando as limitações da sorologia
convencional. A IgM neonatal foi considerada o marcador sorológico
de transmissão. Testes fluorométricos foram realizados para IgG, IgM
(imunocaptura) e avidez de IgG. Cinqüenta e uma das 128 gestantes
testadas tiveram os partos realizados na instituição e a IgM neonatal
foi obtida. Os resultados mostraram 32 (62.75%) gestantes com avidez
alta, índices de IgM entre 0,6 e 2,4 e nenhum recém-nascido infectado.
Dezenove (37.25%) tiveram avidez baixa ou inconclusiva, índices de
IgM entre 0,6 e 11,9, cinco recém-nascidos infectados e um natimorto.
Em dois recém-nascidos infectados e no natimorto, os índices maternos
de IgM foram baixos e em um recém-nascido infectado, o único
parâmetro materno que sugeriu risco para o feto foi a avidez de IgG.
No presente estudo, a avidez de IgG realizada em amostras isoladas de
gestantes IgM positivas auxiliou a determinar o risco de transmissão
durante toda a gestação, especialmente quando os índices dos dois
testes foram analisados em relação à idade gestacional. Este modelo
pode ser menos oneroso para países em desenvolvimento com alta
prevalência da infecção e cria nova perspectiva para o diagnóstico da
toxoplasmose congênita.
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